Apatorsen

Drug Profile

Apatorsen

Alternative Names: ISIS-306053; OGX-427

Latest Information Update: 25 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of British Columbia
  • Developer OncoGenex Pharmaceuticals; Queen Mary Medical School; Sarah Cannon Research Institute
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action HSP27 heat shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Bladder cancer

Highest Development Phases

  • Phase II Non-small cell lung cancer; Pancreatic cancer; Prostate cancer
  • Suspended Bladder cancer
  • Discontinued Breast cancer; Ovarian cancer

Most Recent Events

  • 01 Oct 2017 Hoosier Cancer Research Network completes the phase II Borealis-2 trial for Bladder cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT01780545)
  • 21 Jun 2017 Hoosier Cancer Research Network terminates a phase II trial in Prostate Cancer (Combination therapy, Metastatic disease) in USA and Canada due to lack of accrual (NCT01681433)
  • 05 May 2017 Sarah Cannon Research Institute and OncoGenex Pharmaceuticals completes the phase II Spruce™ trial for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (NCT01829113)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top